The estimated Net Worth of Jay Parrish is at least $127 Tysiąc dollars as of 1 April 2021. Jay Parrish owns over 6,944 units of Vir Biotechnology Inc stock worth over $126,877 and over the last 4 years he sold VIR stock worth over $0. In addition, he makes $0 as Chief Business Officer at Vir Biotechnology Inc.
Sign up
Jay Parrish VIR stock SEC Form 4 insiders trading
Jay has made over 11 trades of the Vir Biotechnology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 6,944 units of VIR stock worth $10,555 on 1 April 2021.
The largest trade he's ever made was exercising 75,000 units of Vir Biotechnology Inc stock on 1 July 2020 worth over $115,500. On average, Jay trades about 25,884 units every 29 days since 2020. As of 1 April 2021 he still owns at least 16,204 units of Vir Biotechnology Inc stock.
You can see the complete history of Jay Parrish stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jay Parrish biography
Dr. Jay Parrish Ph.D. serves as Chief Business Officer of the Company. Prior to that, Dr. Parrish served as our Senior Vice President, Strategy and Corporate Development, from April 2017 to July 2017. Dr. Parrish is a Venture Partner at ARCH Venture Partners, L.P., or ARCH Venture Partners, where he has served since May 2016. From September 2011 to May 2016, Dr. Parrish served in Gilead’s Corporate Development group, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company. Dr. Parrish also served as a scientist in Gilead’s medicinal chemistry group, from March 2004 to September 2011. Since 2012, Dr. Parrish has served as a part-time instructor at UC Berkeley Extension, where he teaches chemistry to undergraduates and post-baccalaureates. He also previously completed a postdoctoral fellowship at the Scripps Research Institute. Dr. Parrish received his B.S. in Chemistry from Emory University, a Ph.D. in Synthetic Organic Chemistry from the University of South Florida and an M.B.A. from the University of California, Berkeley Haas School of Business.
How old is Jay Parrish?
Jay Parrish is 45, he's been the Chief Business Officer of Vir Biotechnology Inc since 2017. There are 20 older and 2 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
What's Jay Parrish's mailing address?
Jay's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO, CA, 94158.
Insiders trading at Vir Biotechnology Inc
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I... oraz Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
What does Vir Biotechnology Inc do?
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
What does Vir Biotechnology Inc's logo look like?
Complete history of Jay Parrish stock trades at Vir Biotechnology Inc
Vir Biotechnology Inc executives and stock owners
Vir Biotechnology Inc executives and other stock owners filed with the SEC include:
-
George Scangos,
President, Chief Executive Officer, Director -
Howard Horn,
Chief Financial Officer, Secretary -
Herbert Virgin,
Executive Vice President of Research and Chief Scientific Officer -
Vicki Sato,
Independent Chairman of the Board -
Dr. Herbert W. Virgin IV, M.D., Ph.D.,
Exec. VP of Research & Chief Scientific Officer -
Dr. Herbert W. Virgin IV,
Exec. VP of Research & Chief Scientific Officer -
Dr. George A. Scangos Ph.D.,
Pres, CEO & Director -
Dr. Ann M. Hanly Ph.D.,
Exec. VP & Chief Technology Officer -
Phil Pang,
Chief Medical Officer -
Dr. George A. Scangos,
Pres, CEO & Director -
Dr. Phillip Pang M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Steven J. Rice,
Chief Admin. Officer -
Saira Ramasastry,
Independent Director -
Robert Perez,
Independent Director -
Phillip Sharp,
Independent Director -
Dr. Klaus Frueh,
Co-Founder & Scientific Advisor -
Robert More,
Independent Director -
Dipchand Nishar,
Independent Director -
Robert Nelsen,
Independent Director -
Elliott Sigal,
Independent Director -
Janet Napolitano,
Director -
Michael Kamarck,
Chief Technology Officer -
Jay Parrish,
Chief Business Officer -
Johanna Friedl-Naderer,
Exec. VP & COO -
Irene Pleasure J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Heather Rowe Armstrong,
VP of Investor Relations -
Dr. Aine M. Hanly Ph.D.,
Chief Technology Officer -
Dr. Louis J. Picker M.D.,
Co-Founder & Scientific Advisor -
Dr. Klaus Frueh Ph.D.,
Co-Founder & Scientific Advisor -
Dr. Neera Dahiya Ravindran M.D., MBA,
VP and Head of Investor Relations & Strategic Communications -
Dr. Louis J. Picker,
Co-Founder & Scientific Advisor -
Dr. Lawrence Corey,
Co-Founder & Scientific Advisor -
Permanent Fund Corp Alaska,
-
& Melinda Gates Foundation ...,
-
Johanna Friedl Naderer,
EVP & Chief Operating Officer -
Steven J. Rice,
Chief Administrative Officer -
Venture Partners Ix, Llcarc...,
-
Endurance (Cayman) Ltd Sb I...,
-
Dhabi Investment Authority ...,
-
Holdings (Private) Ltd Full...,
-
Program Ii (Co Invest Holdi...,
-
Mark Eisner,
EVP and Chief Medical Officer -
Klaus Frueh,
Director -
Venture Partners Ix, Llcarc...,
-
Kristina Burow,
Director -
Jeffrey S. Hatfield,
Director -
Norbert W Bischofberger,
Director -
Ramy Farid,
Director -
Sung Lee,
EVP & Chief Financial Officer -
Ann M. Hanly,
EVP & Chief Technology Officer -
Backer Marianne De,
Chief Executive Officer